Application Notes & Case Studies

  1. Pioneering The End-To-End Decentralized Trial Experience 4/16/2025

    This collaboration highlights the potential of decentralized clinical trials (DCTs) to transform trial execution, as well as offering a replicable model for future research.

  2. Accelerate Your Oncology Breakthroughs 4/16/2025

    Finding the right partnership can help your oncology clinical trials overcome trial complexities through strategic planning, a deep scientific understanding, and operational excellence.

  3. Digital Outcome Measures Approved As Primary Endpoint In Cardiopulmonary Study 4/15/2025

    Discover how a clinical development program was saved using objective, continuous digital outcome measures.

  4. Faster Trial Planning and Site Selection 4/15/2025

    Address the challenges of identifying the most suitable trial sites and investigators while optimizing feasibility planning, reducing screen failure rates, and improving patient retention.

  5. Ergomed's Solutions To The Challenges of Oncology Trials 4/15/2025

    Explore a pivotal Phase III global clinical trial investigating neoadjuvant immunotherapy for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

  6. Strategic Pre-IND Consulting For Gene Therapy In Rare Leukemia 4/11/2025

    Learn about the collaborative efforts of an innovative biotech startup and Ergomed Consulting to overcome challenges in the pre-IND phase for a novel gene therapy targeting a rare form of leukemia.

  7. Early-Stage Development In Rare Pediatric Oncology 4/11/2025

    Learn about the strategic approach a biotechnology company utilized to address significant hurdles in launching a Phase 1 clinical trial for a novel therapy targeting a rare pediatric cancer.

  8. Market Approval For A Novel Non-Hodgkin Lymphoma (NHL) Therapy 4/11/2025

    Explore a collaboration that underscores the importance of strategic planning and regulatory engagement in the approval process.

  9. Post-Market Safety And Risk Management in DMD 4/11/2025

    The pharmaceutical company specializing in rare neurological diseases sought solutions after encountering significant hurdles in post-market safety surveillance.

  10. Setting A New Client Standard In Study Closeout Timelines 4/4/2025

    Learn how a top-10 global pharmaceutical company achieved a significantly faster time to market for a high-profile therapy.